How to buy Synlogic stock (SYBX)

Synlogic is a biotechnology business based in the US. Synlogic shares (SYBX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.39 – an increase of 1.46% over the previous week. Synlogic employs 6 staff and has a trailing 12-month revenue of around $3.2 million.

Our top picks for where to buy Synlogic stock

Buy Synlogic stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Synlogic stock price (NASDAQ: SYBX)

Use our graph to track the performance of SYBX stocks over time.

Synlogic shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.39
52-week range	$1.22 - $5.12
50-day moving average more info button	$1.43
200-day moving average more info button	$1.58
Wall St. target price	$1.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.50

Is it a good time to buy Synlogic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Synlogic price performance over time

Historical closes compared with the close of $1.3817 from 2024-12-23

1 week (2024-12-17)	-4.71%
1 month (2024-11-25)	-0.60%
3 months (2024-09-24)	-10.86%
6 months (2024-06-24)	-9.10%

1 year (2023-12-22)	-62.04%
2 years (2022-12-23)	-86.84%
3 years (2021-12-23)	36.75
5 years (2019-12-24)	36

Synlogic financials

Revenue TTM	$3.2 million
Gross profit TTM	$1.2 million
Return on assets TTM	-46.07%
Return on equity TTM	-158.75%
Profit margin	0%
Book value	$4.64
Market Capitalization more info button	$16 million

TTM: trailing 12 months

Synlogic share dividends

We're not expecting Synlogic to pay a dividend over the next 12 months.

Have Synlogic's shares ever split?

Synlogic's shares were split on a 1:7 basis on 27 August 2017 . So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synlogic shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Synlogic shares which in turn could have impacted Synlogic's share price.

Synlogic share price volatility

Over the last 12 months, Synlogic's shares have ranged in value from as little as $1.22 up to $5.1181. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synlogic's is 0.844. This would suggest that Synlogic's shares are less volatile than average (for this exchange).

Synlogic overview

Synlogic, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc.

Frequently asked questions

What percentage of Synlogic is owned by insiders or institutions?
Currently 14.191% of Synlogic shares are held by insiders and 60.892% by institutions. How many people work for Synlogic?
Latest data suggests 6 work at Synlogic. When does the fiscal year end for Synlogic?
Synlogic's fiscal year ends in December. Where is Synlogic based?
Synlogic's address is: 301 Binney Street, Cambridge, MA, United States, 02142 What is Synlogic's ISIN number?
Synlogic's international securities identification number is: US87166L1008 What is Synlogic's CUSIP number?
Synlogic's Committee on Uniform Securities Identification Procedures number is: 60470J103